Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatin–paclitaxel (CP) ± bevacizumab (BEV): Results from GOG-0218.


Conference Paper

Full Text

Duke Authors

Cited Authors

  • Secord, AA; Tritchler, D; Liu, Y; Starr, MD; Brady, JC; Lankes, HA; Hurwitz, H; Mannel, RS; Tewari, KS; O'Malley, DM; Gray, HJ; Bakkum-Gamez, JN; Fujiwara, K; Boente, M; Deng, W; Burger, RA; Birrer, MJ; Nixon, AB

Published Date

  • May 20, 2016

Published In

Volume / Issue

  • 34 / 15_suppl

Start / End Page

  • 5521 - 5521

Published By

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

International Standard Serial Number (ISSN)

  • 0732-183X

Digital Object Identifier (DOI)

  • 10.1200/jco.2016.34.15_suppl.5521